COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Schett, Georg, Sticherling, Michael, Neurath, Markus F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186927/
https://www.ncbi.nlm.nih.gov/pubmed/32296135
http://dx.doi.org/10.1038/s41577-020-0312-7
_version_ 1783527058806145024
author Schett, Georg
Sticherling, Michael
Neurath, Markus F.
author_facet Schett, Georg
Sticherling, Michael
Neurath, Markus F.
author_sort Schett, Georg
collection PubMed
description COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection.
format Online
Article
Text
id pubmed-7186927
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71869272020-04-28 COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett, Georg Sticherling, Michael Neurath, Markus F. Nat Rev Immunol Comment COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection. Nature Publishing Group UK 2020-04-15 2020 /pmc/articles/PMC7186927/ /pubmed/32296135 http://dx.doi.org/10.1038/s41577-020-0312-7 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Schett, Georg
Sticherling, Michael
Neurath, Markus F.
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title_full COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title_fullStr COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title_full_unstemmed COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title_short COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
title_sort covid-19: risk for cytokine targeting in chronic inflammatory diseases?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186927/
https://www.ncbi.nlm.nih.gov/pubmed/32296135
http://dx.doi.org/10.1038/s41577-020-0312-7
work_keys_str_mv AT schettgeorg covid19riskforcytokinetargetinginchronicinflammatorydiseases
AT sticherlingmichael covid19riskforcytokinetargetinginchronicinflammatorydiseases
AT neurathmarkusf covid19riskforcytokinetargetinginchronicinflammatorydiseases

Ejemplares similares